- Home
- MURA vs SPWRW Comparison
MURA vs SPWRW Comparison
Compare MURA & SPWRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- SPWRW
- Stock Information
- Founded
- MURA 2013
- SPWRW N/A
- Country
- MURA Ireland
- SPWRW United States
- Employees
- MURA N/A
- SPWRW N/A
- Industry
- MURA
- SPWRW Semiconductors
- Sector
- MURA
- SPWRW Technology
- Exchange
- MURA Nasdaq
- SPWRW Nasdaq
- Market Cap
- MURA 17.7M
- SPWRW 15.5M
- IPO Year
- MURA N/A
- SPWRW N/A
- Fundamental
- Price
- MURA $2.63
- SPWRW $0.20
- Analyst Decision
- MURA Strong Buy
- SPWRW
- Analyst Count
- MURA 4
- SPWRW 0
- Target Price
- MURA $13.00
- SPWRW N/A
- AVG Volume (30 Days)
- MURA 14.0M
- SPWRW N/A
- Earning Date
- MURA 05-20-2025
- SPWRW N/A
- Dividend Yield
- MURA N/A
- SPWRW N/A
- EPS Growth
- MURA N/A
- SPWRW N/A
- EPS
- MURA N/A
- SPWRW N/A
- Revenue
- MURA N/A
- SPWRW N/A
- Revenue This Year
- MURA $34.35
- SPWRW N/A
- Revenue Next Year
- MURA N/A
- SPWRW N/A
- P/E Ratio
- MURA N/A
- SPWRW N/A
- Revenue Growth
- MURA N/A
- SPWRW N/A
- 52 Week Low
- MURA $0.95
- SPWRW N/A
- 52 Week High
- MURA $4.74
- SPWRW N/A
- Technical
- Relative Strength Index (RSI)
- MURA 56.94
- SPWRW N/A
- Support Level
- MURA $2.48
- SPWRW N/A
- Resistance Level
- MURA $2.66
- SPWRW N/A
- Average True Range (ATR)
- MURA 0.12
- SPWRW 0.00
- MACD
- MURA 0.04
- SPWRW 0.00
- Stochastic Oscillator
- MURA 42.58
- SPWRW 0.00
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.